NCT00863369View on ClinicalTrials.gov

Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 29, 2005

Primary Completion Date

August 25, 2016

Study Completion Date

June 20, 2023

Conditions
Lymphoma
Interventions
BIOLOGICAL

rituximab

Given IV

DRUG

bortezomib

Given IV

DRUG

gemcitabine hydrochloride

Given IV

OTHER

questionnaire administration

Ancillary studies

Trial Locations (2)

91030

South Pasadena Cancer Center, South Pasadena

91010-3000

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT00863369 - Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter